1. A cardiology fellow asks an attending to explain how ranolazine reduces myocardial ischemia. Which of the following correctly describes ranolazine's primary anti-ischemic mechanism?
A) It reduces heart rate by blocking beta-1 adrenergic receptors in the sinoatrial node, decreasing myocardial oxygen demand
B) It selectively inhibits the late inward sodium current (late INa) in cardiac myocytes, reducing intracellular sodium and calcium overload during ischemia without altering heart rate, blood pressure, or contractility
C) It blocks L-type calcium channels in vascular smooth muscle, reducing afterload and myocardial oxygen consumption
D) It activates ATP-sensitive potassium channels in vascular smooth muscle, producing coronary vasodilation and preload reduction
E) It inhibits the funny current (If) in sinoatrial node pacemaker cells, slowing spontaneous depolarization and reducing heart rate
ANSWER: B
Rationale:
Ranolazine's anti-ischemic mechanism is mechanistically distinct from all conventional antianginal agents. Its primary target is the late inward sodium current (late INa) — the small residual sodium influx that persists through the action potential plateau (phases 2-3) in cardiac myocytes. Under ischemic conditions, late INa increases 5-10 fold, driving persistent Na+ influx that overloads the Na+/Ca2+ exchanger (NCX), leading to intracellular calcium accumulation, diastolic dysfunction, elevated left ventricular end-diastolic pressure, and worsened subendocardial ischemia. Ranolazine selectively blocks this late INa, breaking the ischemia-Na+-Ca2+ overload cycle. Critically, at therapeutic doses, ranolazine produces NO significant effect on heart rate, blood pressure, contractility, or AV conduction — this hemodynamically neutral profile distinguishes it from all other antianginal classes.
Option A: Option A describes beta-blocker mechanism.
Option C: Option C describes calcium channel blocker (CCB) mechanism.
Option D: Option D describes nicorandil's KATP-opening mechanism.
Option E: Option E describes ivabradine's If-channel mechanism.
2. During myocardial ischemia, the late inward sodium current (late INa) increases substantially. Which sequence correctly describes how this leads to worsened ischemia, and which step does ranolazine interrupt?
A) Increased late INa → K+ efflux → membrane hyperpolarization → coronary vasoconstriction → worsened ischemia; ranolazine blocks K+ efflux
B) Increased late INa → reduced intracellular Na+ → NCX (Na+/Ca2+ exchanger) overactivation → Ca2+ extrusion → diastolic hyperfunction; ranolazine restores Na+ influx
C) Increased late INa → elevated intracellular Na+ → NCX inhibition → intracellular Ca2+ accumulation → diastolic dysfunction and elevated LVEDP → worsened subendocardial ischemia; ranolazine selectively blocks late INa at the first step
D) Increased late INa → mitochondrial depolarization → impaired fatty acid oxidation → ATP depletion → contractile failure; ranolazine restores mitochondrial membrane potential
E) Increased late INa → prolonged phase 0 depolarization → slowed AV conduction → reduced cardiac output → worsened ischemia; ranolazine shortens phase 0
ANSWER: C
Rationale:
The ischemia-Na+-Ca2+ overload cycle is the central mechanistic concept underlying ranolazine's anti-ischemic action. During ischemia, hypoxia, and oxidative stress, the late inward sodium current (late INa) — a small residual Na+ influx persisting through the action potential plateau — increases 5-10 fold above baseline. This drives persistent Na+ entry into cardiac myocytes, elevating intracellular Na+ concentration. The Na+/Ca2+ exchanger (NCX), which normally extrudes one Ca2+ ion in exchange for three Na+ ions entering, is inhibited (or reverses) when intracellular Na+ rises: NCX can no longer efficiently extrude Ca2+, leading to progressive intracellular Ca2+ accumulation. This calcium overload impairs diastolic relaxation, raises left ventricular end-diastolic pressure (LVEDP), compresses subendocardial perfusion pressure, and worsens ischemia — a self-amplifying cycle. Ranolazine selectively blocks late INa, interrupting this cycle at its origin.
Option A: Option A incorrectly describes K+ efflux and vasoconstriction — not part of this pathway.
Option B: Option B inverts the Na+ change (late INa raises, not lowers, intracellular Na+).
Option D: Option D describes trimetazidine's metabolic mechanism, not ranolazine's.
Option E: Option E incorrectly attributes ranolazine's action to phase 0 — ranolazine has negligible effect on peak INa (phase 0) at therapeutic doses.
3. A 61-year-old man with chronic stable angina continues to have two to three anginal episodes per week despite maximum-dose amlodipine 10 mg daily and metoprolol succinate 200 mg daily. His resting heart rate is 58 bpm and blood pressure is 118/72 mmHg. His cardiologist considers adding ranolazine. Which of the following best describes the FDA-approved indication for ranolazine that applies to this patient?
A) First-line monotherapy for chronic stable angina in patients with normal left ventricular function
B) Acute relief of anginal episodes in patients with refractory coronary artery disease
C) Chronic stable angina in patients with left ventricular ejection fraction below 40% who cannot tolerate beta-blockers
D) Vasospastic angina in patients with angiographically normal coronary arteries who have failed nitrate therapy
E) Chronic stable angina as add-on therapy in patients who remain symptomatic despite adequate doses of other antianginal agents such as beta-blockers, calcium channel blockers, or nitrates
ANSWER: E
Rationale:
Ranolazine carries an FDA-approved indication for chronic stable angina as add-on (adjunctive) therapy in patients who remain symptomatic on adequate doses of conventional antianginal agents — beta-blockers, calcium channel blockers (CCBs), or nitrates. The patient in this scenario fits this indication precisely: he has chronic stable angina with persistent symptoms despite maximum-dose CCB and beta-blocker therapy. Three important constraints define appropriate ranolazine use: (1) it is approved only as add-on therapy, not monotherapy; (2) it is extended-release only and has no role in acute angina relief (onset is too slow); and (3) it is not approved for vasospastic angina (vasospasm is driven by coronary smooth muscle hyperreactivity, not myocyte late INa excess; evidence for ranolazine in vasospasm is absent).
Option A: Option A is incorrect — ranolazine is not approved as monotherapy and is not a first-line agent.
Option B: Option B is incorrect — ranolazine is an extended-release formulation with no acute antianginal role.
Option C: Option C is incorrect — ejection fraction below 40% is not a criterion for the angina indication (though ranolazine was studied in this population in MERLIN-TIMI 36).
Option D: Option D is incorrect — ranolazine is not approved for vasospastic angina.
4. The CARISA trial (Chaitman et al., 2004) was a pivotal study establishing ranolazine's antianginal efficacy. Which of the following correctly describes the trial design and its most important mechanistic finding?
A) CARISA enrolled 823 patients with chronic stable angina on background atenolol, amlodipine, or diltiazem; ranolazine significantly increased exercise duration and time to angina onset with no difference in heart rate or blood pressure between groups, confirming ranolazine's hemodynamically neutral anti-ischemic mechanism
B) CARISA enrolled 6,560 patients with non-ST-elevation acute coronary syndrome on standard ACS therapy; ranolazine reduced recurrent ischemia and new-onset atrial fibrillation but did not significantly reduce the primary composite endpoint of cardiovascular death, myocardial infarction, or recurrent ischemia
C) CARISA enrolled 565 patients already on maximum-dose amlodipine 10 mg daily; adding ranolazine 1000 mg twice daily significantly reduced weekly anginal episodes and sublingual nitroglycerin use compared to placebo
D) CARISA enrolled 823 patients with chronic stable angina and demonstrated that ranolazine significantly reduced heart rate and blood pressure compared to placebo, explaining its anti-ischemic benefit through hemodynamic offloading
E) CARISA enrolled 10,917 patients with stable coronary artery disease and left ventricular dysfunction; ranolazine reduced hospital admissions for myocardial infarction and coronary revascularization in the prespecified subgroup with angina and heart rate above 70 bpm
ANSWER: A
Rationale:
The CARISA trial enrolled 823 patients with chronic stable angina already on background antianginal therapy — specifically atenolol (a beta-blocker), amlodipine (a dihydropyridine CCB), or diltiazem (a non-dihydropyridine CCB). Ranolazine 750 mg or 1000 mg twice daily versus placebo significantly increased exercise duration, time to ST-segment depression on exercise testing, and time to anginal onset, and reduced weekly anginal episodes and sublingual nitroglycerin (SL-NTG) use. The critical mechanistic finding was that there was NO statistically significant difference in heart rate or blood pressure between the ranolazine and placebo groups — directly confirming that ranolazine's anti-ischemic benefit is not mediated through hemodynamic changes but through its late INa inhibitory mechanism.
Option B: Option B describes the MERLIN-TIMI 36 trial (Morrow et al., 2007), which studied NSTE-ACS patients.
Option C: Option C describes the ERICA trial (Stone et al., 2006), which specifically studied add-on to maximum-dose amlodipine.
Option D: Option D incorrectly states that CARISA showed HR and BP reduction — the opposite is true; the absence of hemodynamic change was the mechanistically significant finding.
Option E: Option E describes the BEAUTIFUL trial (Fox et al., 2008), which studied ivabradine in stable CAD with LV dysfunction.
5. A 58-year-old man with chronic stable angina is on ranolazine 1000 mg twice daily with good symptom control. He is diagnosed with a Candida esophagitis and his gastroenterologist prescribes ketoconazole. Which of the following best describes the correct management of this drug interaction?
A) Reduce ranolazine to 500 mg twice daily and monitor QTc at two-week intervals while ketoconazole therapy continues
B) Continue both drugs at current doses and obtain a baseline ECG; repeat QTc monitoring monthly during concurrent use
C) Discontinue ketoconazole and substitute with a topical antifungal agent that does not require systemic absorption, avoiding the interaction entirely
D) Ketoconazole is a strong CYP3A4 inhibitor that increases ranolazine plasma levels 3.5- to 4.5-fold; concurrent use is contraindicated, and an alternative antifungal agent that does not strongly inhibit CYP3A4 should be selected
E) Add a QT-shortening agent such as magnesium supplementation and reduce ranolazine to 750 mg twice daily to manage the interaction while maintaining antianginal efficacy
ANSWER: D
Rationale:
Ranolazine is primarily metabolized by CYP3A4 (cytochrome P450 3A4). Ketoconazole is a prototypical strong CYP3A4 inhibitor. When strong CYP3A4 inhibitors — including ketoconazole, clarithromycin, and ritonavir — are co-administered with ranolazine, plasma ranolazine concentrations increase 3.5- to 4.5-fold. This degree of exposure amplification dramatically increases the risk of dose-dependent adverse effects, most critically QTc prolongation and the risk of torsades de pointes (TdP). The FDA prescribing information for ranolazine lists concurrent use with strong CYP3A4 inhibitors as a contraindication — not merely a dose-adjustment situation. The correct management is to select an alternative antifungal agent that does not strongly inhibit CYP3A4 (such as fluconazole with caution as a moderate inhibitor, or an echinocandin).
Option A: Option A is incorrect — dose reduction to 500 mg BID is the management strategy for moderate CYP3A4 inhibitors (diltiazem, verapamil, erythromycin), not strong inhibitors; strong inhibitor co-administration is contraindicated regardless of dose.
Option B: Option B is incorrect — monitoring does not resolve a contraindicated pharmacokinetic interaction.
Option C: Option C represents one valid approach if topical therapy is clinically appropriate, but Option D more precisely names the pharmacological reason and the contraindication.
Option E: Option E is incorrect — there is no established QT-shortening intervention that renders a contraindicated drug combination safe.
6. A 66-year-old woman with chronic stable angina inadequately controlled on metoprolol succinate and isosorbide mononitrate is being evaluated for addition of ranolazine. Her baseline ECG shows a QTc interval of 514 ms. She has no electrolyte abnormalities and is not on any other QT-prolonging agents. Which of the following is the most appropriate next step?
A) Start ranolazine 500 mg twice daily (the lower dose) because the risk of additional QTc prolongation is minimal at the starting dose, and reassess QTc in four weeks
B) Do not initiate ranolazine; a baseline QTc exceeding 500 ms is a contraindication to ranolazine use because the drug produces dose-dependent QTc prolongation and the margin of safety is already exhausted
C) Start ranolazine 1000 mg twice daily immediately because the anti-ischemic benefit of late INa inhibition outweighs the QTc risk in a patient with symptomatic angina
D) Initiate ranolazine 500 mg twice daily and add magnesium supplementation concurrently to offset QTc prolongation
E) Start ranolazine only if the patient agrees to continuous ambulatory cardiac monitoring for the first 30 days of therapy
ANSWER: B
Rationale:
Ranolazine produces dose-dependent QTc prolongation through weak inhibition of the hERG potassium channel (IKr): approximately 6 ms at 500 mg twice daily and 9-14 ms at 1000 mg twice daily. In a patient whose baseline QTc is already 514 ms, even the lower degree of additional prolongation associated with ranolazine would push the QTc further above the 500 ms threshold — the level at which risk of torsades de pointes (TdP), a potentially fatal ventricular arrhythmia, increases substantially. The FDA prescribing information for ranolazine lists a baseline QTc exceeding 500 ms as a contraindication. The correct approach is to withhold ranolazine and identify an alternative add-on agent that does not prolong the QTc — for example, ivabradine if the patient is in sinus rhythm with resting HR ≥70 bpm.
Option A: Option A is incorrect — there is no dose of ranolazine that is safe when baseline QTc is already above 500 ms; the contraindication applies to all doses.
Option C: Option C is incorrect — clinical benefit does not override a contraindication based on established safety thresholds.
Option D: Option D is incorrect — magnesium supplementation does not reliably or sufficiently counteract drug-induced QTc prolongation to render a contraindicated combination safe.
Option E: Option E is incorrect — monitoring is not a substitute for respecting an absolute contraindication.
7. A pharmacology student asks how ivabradine reduces heart rate without affecting contractility or blood pressure. Which of the following correctly describes ivabradine's mechanism of action?
A) Ivabradine blocks beta-1 adrenergic receptors in the sinoatrial node, preventing catecholamine-driven increases in heart rate while partially sparing cardiac contractility at low doses
B) Ivabradine blocks L-type calcium channels selectively in the sinoatrial node, slowing spontaneous depolarization without affecting the L-type channels in ventricular myocytes that support contractility
C) Ivabradine selectively blocks HCN (hyperpolarization-activated cyclic nucleotide-gated) channels in sinoatrial node pacemaker cells, inhibiting the funny current (If) — the mixed Na+/K+ inward current responsible for spontaneous phase 4 depolarization — thereby slowing heart rate without any effect on contractility, blood pressure, AV conduction, or ventricular repolarization
D) Ivabradine inhibits the Na+/K+-ATPase pump in sinoatrial node cells, reducing the electrochemical gradient that drives spontaneous phase 4 depolarization and slowing heart rate
E) Ivabradine opens ATP-sensitive potassium channels in the sinoatrial node, hyperpolarizing pacemaker cells and slowing spontaneous depolarization while preserving ventricular function
ANSWER: C
Rationale:
Ivabradine's heart rate reduction operates through a unique and highly specific mechanism. The funny current (If) is a mixed inward Na+/K+ current that activates during hyperpolarization in sinoatrial (SA) node pacemaker cells. It is conducted through HCN (hyperpolarization-activated cyclic nucleotide-gated) channels and is directly responsible for the slow spontaneous depolarization during phase 4 of the SA node action potential — the pacemaker potential. The rate at which phase 4 depolarization reaches threshold determines heart rate. If magnitude is also upregulated by cAMP (explaining catecholamine-driven tachycardia). Ivabradine acts as a selective open-channel blocker of HCN channels in SA node cells, slowing phase 4 depolarization and reducing heart rate in a dose-dependent, rate-dependent manner. Because HCN channels have no role in ventricular contractility (which depends on L-type Ca2+ channels and the Frank-Starling mechanism), ivabradine produces absolutely no negative inotropic effect, no change in blood pressure, no effect on AV conduction, and no QTc prolongation.
Option A: Option A describes beta-blocker mechanism — ivabradine is not an adrenergic receptor antagonist.
Option B: Option B describes a selective L-type calcium channel mechanism — ivabradine does not act on L-type calcium channels.
Option D: Option D describes digoxin-like Na+/K+-ATPase inhibition — not ivabradine's mechanism.
Option E: Option E describes KATP channel opening — the mechanism of nicorandil, not ivabradine.
8. A 72-year-old man with stable angina and permanent atrial fibrillation (AF) has a resting ventricular rate of 88 bpm despite digoxin 0.25 mg daily. His cardiologist considers adding ivabradine to reduce heart rate and improve his anginal symptoms. Which of the following is the most accurate statement about this plan?
A) Ivabradine is appropriate because it reduces ventricular rate in AF through HCN channel blockade in the AV node, independent of sinoatrial node activity
B) Ivabradine can be used cautiously in AF at a reduced dose of 2.5 mg twice daily because its rate-slowing effect is partially preserved in irregular rhythms
C) Ivabradine is relatively contraindicated in AF but may be used if the resting ventricular rate exceeds 100 bpm and other rate-control options have been exhausted
D) Ivabradine should be added at 5 mg twice daily because the funny current (If) is upregulated in AF, making ivabradine more effective in this rhythm than in sinus rhythm
E) Ivabradine is contraindicated in atrial fibrillation; its mechanism — HCN channel blockade in the sinoatrial node — has no effect on ventricular rate in AF because the sinoatrial node is not generating the rhythm; prescribing ivabradine in AF provides no rate control and exposes the patient to adverse effects without benefit
ANSWER: E
Rationale:
Ivabradine's mechanism is anatomically and functionally specific to the sinoatrial (SA) node. Its target — HCN channels conducting the funny current (If) — is expressed in SA node pacemaker cells, where If drives spontaneous phase 4 depolarization and determines heart rate in sinus rhythm. In atrial fibrillation, the SA node is suppressed by chaotic atrial electrical activity; it is not generating the rhythm, and the ventricular rate is determined by how much of that chaotic activity conducts through the AV node. Ivabradine has no action on AV nodal conduction — blocking HCN channels in the SA node does nothing to limit AV conduction in AF. The result is that ivabradine provides absolutely no ventricular rate control in AF while still exposing the patient to its adverse effects (phosphenes, bradycardia risk if sinus rhythm intermittently resumes, CYP3A4 interactions). Atrial fibrillation and flutter are listed as absolute contraindications in the ivabradine prescribing information; confirmation of sinus rhythm on ECG is required before initiation and at follow-up visits.
Option A: Option A is incorrect — ivabradine has no action on AV nodal HCN channels at therapeutic concentrations.
Option B: Option B is incorrect — there is no partial preservation of effect in AF; the effect is zero.
Option C: Option C is incorrect — rate above 100 bpm does not create an exception to the contraindication.
Option D: Option D is incorrect — If upregulation in AF does not restore SA node control of ventricular rate.
9. The SIGNIFY trial (Fox et al., 2014) had important regulatory consequences for ivabradine prescribing in stable coronary artery disease. Which of the following correctly summarizes the trial's findings and what changed in clinical practice as a result?
A) SIGNIFY enrolled 6,558 patients with heart failure with reduced ejection fraction (HFrEF) and demonstrated an 18% reduction in the composite of cardiovascular death and hospital admission for worsening heart failure, establishing the HFrEF FDA indication for ivabradine
B) SIGNIFY enrolled 19,102 patients with stable coronary artery disease without heart failure and resting heart rate at or above 70 bpm; the primary endpoint of cardiovascular death or nonfatal myocardial infarction was not significantly reduced; in the angina subgroup receiving ivabradine 7.5 mg twice daily, the incidence of primary endpoint events was significantly increased, leading regulatory agencies to cap the ivabradine dose at 5 mg twice daily for stable angina without heart failure
C) SIGNIFY enrolled 10,917 patients with stable coronary artery disease and left ventricular ejection fraction below 40%; while the overall primary endpoint was not met, a prespecified subgroup with resting heart rate at or above 70 bpm and angina showed significantly reduced hospital admissions for myocardial infarction and revascularization
D) SIGNIFY enrolled 19,102 patients with stable coronary artery disease and demonstrated that ivabradine 7.5 mg twice daily significantly reduced cardiovascular mortality and myocardial infarction, confirming the mortality benefit of heart rate reduction in stable coronary disease
E) SIGNIFY enrolled 565 patients with chronic stable angina on maximum-dose amlodipine and showed that adding ivabradine significantly reduced anginal episodes and sublingual nitroglycerin use, supporting its use as add-on to dihydropyridine calcium channel blockers
ANSWER: B
Rationale:
The SIGNIFY trial enrolled 19,102 patients with stable coronary artery disease (CAD) without heart failure who had a resting heart rate at or above 70 bpm, all on standard background therapy. This was the largest ivabradine trial in stable CAD without heart failure. The primary endpoint — the composite of cardiovascular death or nonfatal myocardial infarction — was NOT significantly reduced in the overall trial population. More importantly, in a prespecified subgroup of patients with angina who were randomized to the higher ivabradine dose of 7.5 mg twice daily, there was a statistically significant increase in the primary endpoint incidence. The precise mechanism underlying this harm signal is not fully established, but it generated a regulatory response: most regulatory agencies subsequently capped the ivabradine dose for stable angina without heart failure at 5 mg twice daily (not 7.5 mg), and the prescribing information was updated accordingly. This dose constraint is clinically important — 7.5 mg BID remains appropriate in HFrEF (where SHIFT data support it) but not in stable angina without heart failure. Option D is factually incorrect — SIGNIFY did not demonstrate mortality benefit.
Option A: Option A describes the SHIFT trial (Swedberg et al., 2010), which studied ivabradine in HFrEF.
Option C: Option C describes the BEAUTIFUL trial (Fox et al., 2008), which studied stable CAD with LV dysfunction.
Option E: Option E describes the ERICA trial design applied incorrectly to ivabradine.
10. A 64-year-old man has heart failure with reduced ejection fraction (HFrEF; EF 32%), sinus rhythm, and a resting heart rate of 76 bpm despite carvedilol 25 mg twice daily, which is the maximum tolerated dose. He also has stable angina. His cardiologist considers adding ivabradine. Which trial provides the strongest evidence supporting ivabradine use in this patient, and what was its key finding?
A) The CARISA trial demonstrated that ivabradine added to background beta-blocker, amlodipine, or diltiazem significantly increased exercise duration and reduced anginal frequency in patients with HFrEF and stable angina, supporting its add-on role
B) The BEAUTIFUL trial demonstrated that ivabradine significantly reduced the primary endpoint of cardiovascular death plus hospital admission for myocardial infarction or heart failure in all patients with stable CAD and EF below 40%, establishing routine use in HFrEF
C) The SIGNIFY trial demonstrated that ivabradine 7.5 mg twice daily significantly reduced cardiovascular mortality in patients with HFrEF and stable angina, and this formed the basis of the FDA heart failure indication
D) The SHIFT trial enrolled 6,558 patients with HFrEF (EF ≤35%), sinus rhythm, and resting heart rate at or above 70 bpm despite maximally tolerated beta-blocker therapy, and demonstrated an 18% significant reduction in the composite of cardiovascular death and hospital admission for worsening heart failure, providing the evidence base for the FDA HFrEF indication for ivabradine
E) The MERLIN-TIMI 36 trial demonstrated that ivabradine reduced recurrent ischemia and ventricular arrhythmias in patients with HFrEF who presented with non-ST-elevation acute coronary syndrome, supporting its use in this population
ANSWER: D
Rationale:
The SHIFT trial (Swedberg et al., 2010) enrolled 6,558 patients with HFrEF (defined as EF ≤35%), sinus rhythm, and resting heart rate at or above 70 bpm despite maximally tolerated beta-blocker doses. This patient profile matches the man described: EF 32%, sinus rhythm, HR 76 bpm, carvedilol at maximum tolerated dose. SHIFT demonstrated a significant 18% relative reduction in the primary composite endpoint of cardiovascular death and hospital admission for worsening heart failure — a clinically meaningful result in a high-risk population. This trial provided the evidence base for the FDA approval of ivabradine for HFrEF. In a patient like this one who has both HFrEF and stable angina, ivabradine offers the advantage of addressing both conditions simultaneously with a single agent.
Option A: Option A is incorrect — CARISA studied ranolazine, not ivabradine, and enrolled stable angina patients without HFrEF as a defining criterion.
Option B: Option B is incorrect — BEAUTIFUL did not meet its overall primary endpoint; the reduction in MI and revascularization was seen only in a prespecified angina subgroup.
Option C: Option C is incorrect — SIGNIFY studied stable CAD without heart failure and did not show mortality benefit; the higher 7.5 mg dose in the angina subgroup was associated with harm.
Option E: Option E is incorrect — MERLIN-TIMI 36 studied ranolazine, not ivabradine, and focused on NSTE-ACS.
11. A 59-year-old woman started on ivabradine 5 mg twice daily for stable angina returns to clinic six weeks later reporting episodes of bright flashes and colored halos in her visual field that occur when she enters a darkened room or when oncoming headlights hit her eyes at night. Her vision is otherwise normal and ophthalmological examination is unremarkable. Which of the following best explains this adverse effect?
A) Ivabradine causes phosphenes — transient luminous visual phenomena including bright flashes, halos, and colored patterns triggered by sudden changes in light intensity — because HCN (hyperpolarization-activated cyclic nucleotide-gated) channels are expressed in retinal cells as well as the sinoatrial node, and ivabradine's HCN blockade in the retina alters light-adaptation signaling; this effect occurs in approximately 14-18% of patients, is completely reversible on dose reduction or discontinuation, and all patients must be counseled before starting the drug
B) Ivabradine causes retinal ischemia by reducing cardiac output through excessive heart rate reduction, causing transient visual disturbances in the peripheral retina that resolve when heart rate normalizes above 60 bpm
C) Ivabradine blocks L-type calcium channels in retinal photoreceptors as an off-target effect, impairing calcium-dependent phototransduction and producing transient visual phenomena at high plasma concentrations
D) Ivabradine causes visual disturbances through direct optic nerve compression from drug-induced increases in intracranial pressure, a rare but recognized adverse effect that requires urgent ophthalmological evaluation
E) Ivabradine displaces retinol (vitamin A) from its binding protein in the retinal pigment epithelium, transiently impairing rhodopsin regeneration and causing dark adaptation failure that presents as bright halos and flashes
ANSWER: A
Rationale:
Phosphenes are the most distinctive and class-specific adverse effect of ivabradine, and the mechanism directly reflects the drug's pharmacological target. HCN (hyperpolarization-activated cyclic nucleotide-gated) channels — the same channel family that conducts the funny current (If) in the sinoatrial node — are also expressed in retinal cells, where they play a role in light adaptation and photoreceptor signaling. Ivabradine's HCN channel blockade in retinal cells alters light-adaptation responses, producing transient luminous visual phenomena (phosphenes) characterized by bright flashes, halos, and colored patterns that are reliably triggered by sudden changes in light intensity — entering a dark room, encountering headlights at night, or transitioning from bright to dim environments. The incidence is approximately 14-18% in clinical trials (versus ~5% for placebo). These phenomena typically appear within the first two months of therapy and diminish over time. They are completely reversible on dose reduction or discontinuation. Critically, because unexpected bright visual phenomena while driving at night can be alarming and dangerous, all patients must receive explicit counseling about phosphenes before ivabradine is initiated — failure to do so commonly leads to abrupt self-discontinuation.
Option B: Option B is incorrect — phosphenes are not caused by reduced cardiac output or retinal ischemia; they are a pharmacodynamic off-target effect at the same molecular target.
Option C: Option C is incorrect — ivabradine does not meaningfully block L-type calcium channels.
Option D: Option D is incorrect — ivabradine does not cause intracranial hypertension.
Option E: Option E is incorrect — ivabradine has no interaction with retinol or rhodopsin metabolism.
12. A cardiologist is selecting a heart rate-reducing agent for a patient with stable angina, sinus rhythm, and a left ventricular ejection fraction of 38%. The patient's resting heart rate remains 78 bpm despite carvedilol at the maximum tolerated dose. Which of the following best describes the principal pharmacological advantage of adding ivabradine rather than increasing beta-blocker dose in this patient?
A) Ivabradine produces greater absolute heart rate reduction than beta-blockers at equivalent doses because its rate-dependent mechanism amplifies the effect at higher baseline heart rates, making it more potent for rate control in tachycardic patients
B) Ivabradine avoids the CYP2D6 drug interactions associated with metoprolol and carvedilol, making it a safer choice in patients on polypharmacy without requiring therapeutic drug monitoring
C) Ivabradine reduces heart rate through HCN channel blockade in the sinoatrial node without any negative inotropic effect — contractility is fully preserved — providing heart rate reduction in a patient with compromised left ventricular function without the risk of further depression of cardiac output that would accompany an increase in beta-blocker dose
D) Ivabradine eliminates the risk of bronchospasm associated with beta-blockers, making it the preferred agent for heart rate reduction in any patient with concurrent obstructive airway disease and reduced ejection fraction
E) Ivabradine is preferred over beta-blockers in all patients with reduced ejection fraction because it does not suppress the renin-angiotensin-aldosterone system, preserving the compensatory neurohormonal responses that maintain cardiac output in heart failure
ANSWER: C
Rationale:
The principal clinical advantage of ivabradine over beta-blockers for heart rate reduction is the complete preservation of cardiac contractility (inotropy). Beta-blockers reduce heart rate through beta-1 adrenergic receptor blockade — a mechanism that simultaneously reduces heart rate, contractility, and blood pressure. In a patient whose ejection fraction is already 38% and who is at maximum tolerated beta-blocker dose, further uptitration of beta-blockade carries significant risk of worsening contractile function and further reducing cardiac output. Ivabradine achieves heart rate reduction exclusively through HCN channel blockade in the SA node: it slows spontaneous phase 4 depolarization and reduces HR in a dose-dependent, rate-dependent manner with absolutely no negative inotropic effect, no reduction in blood pressure, and no effect on AV conduction or ventricular repolarization. This makes ivabradine the appropriate add-on when HR remains elevated at maximum tolerated beta-blocker dose, precisely because it provides additional HR benefit without the contractility penalty.
Option A: Option A is incorrect — while ivabradine does have a rate-dependent property (greater effect at higher HR), this does not mean it is more potent than beta-blockers as a class; the comparison is more nuanced.
Option B: Option B is incorrect — while true that ivabradine avoids beta-blocker-specific CYP2D6 interactions, ivabradine itself is a CYP3A4 substrate with its own interaction profile; this is not its principal advantage.
Option D: Option D is incorrect — while avoiding bronchospasm is a genuine advantage, the question asks about the principal pharmacological advantage in the context of reduced EF, which is the contractility issue.
Option E: Option E is incorrect — the rationale misrepresents both beta-blocker and ivabradine pharmacology; beta-blockers are a cornerstone of HFrEF therapy and do not need to be replaced by ivabradine for neurohormonal reasons.
13. A pharmacology lecturer asks students to identify the antianginal agent that works through two distinct mechanisms simultaneously — one involving potassium channels and one resembling the mechanism of organic nitrates. Which of the following correctly identifies this drug and describes both of its mechanisms?
A) Ranolazine — it opens ATP-sensitive potassium channels in vascular smooth muscle to reduce afterload, and also inhibits late INa in cardiac myocytes to reduce intracellular calcium overload, providing dual antianginal benefit through hemodynamic and myocyte-level mechanisms
B) Ivabradine — it blocks HCN channels in the sinoatrial node to reduce heart rate, and also activates guanylyl cyclase in vascular smooth muscle via nitric oxide release, producing vasodilation that complements the heart rate-reducing effect
C) Trimetazidine — it inhibits long-chain 3-ketoacyl-CoA thiolase to shift myocardial metabolism toward glucose oxidation, and also releases nitric oxide in coronary arteries to produce vasodilation and improve coronary blood flow during ischemia
D) Isosorbide mononitrate — it releases nitric oxide through hepatic metabolism to activate guanylyl cyclase, and also opens ATP-sensitive potassium channels in mitochondria to produce cardioprotective preconditioning similar to ischemic preconditioning
E) Nicorandil — it opens ATP-sensitive potassium channels (KATP channels) in vascular smooth muscle, causing K+ efflux, membrane hyperpolarization, closure of voltage-gated calcium channels, and vasodilation; and it also releases nitric oxide through a nitrate-like component, activating guanylyl cyclase to produce venodilation via cyclic GMP; the combined result is balanced preload and afterload reduction along with a cardioprotective preconditioning effect through mitochondrial KATP channel opening
ANSWER: E
Rationale:
Nicorandil is the dual-mechanism antianginal agent that combines KATP channel opening with a nitrate-like nitric oxide (NO)-releasing component. Its first mechanism operates through ATP-sensitive potassium (KATP) channels in vascular smooth muscle: nicorandil opens these channels, producing K+ efflux that hyperpolarizes the cell membrane. Hyperpolarization closes voltage-gated L-type calcium channels, reducing intracellular Ca2+ and producing vasodilation of both coronary arteries and peripheral arterioles — lowering both preload and afterload. Nicorandil also opens mitochondrial KATP channels, triggering a cardioprotective preconditioning effect that mimics ischemic preconditioning and reduces experimental infarct size. Its second mechanism is a nitrate-like component: nicorandil releases NO, which activates soluble guanylyl cyclase, raises cyclic GMP (cGMP), and produces venodilation — reducing preload through the same pathway as organic nitrates. Cross-tolerance with organic nitrates may occur with this component (though less prominent than with pure nitrates). The combined hemodynamic profile — balanced preload and afterload reduction, coronary vasodilation, and cardioprotective preconditioning — is pharmacologically distinct from any single conventional antianginal class.
Option A: Option A is incorrect — ranolazine does not open KATP channels; its mechanism is late INa inhibition only.
Option B: Option B is incorrect — ivabradine does not release NO; its sole mechanism is HCN/If blockade.
Option C: Option C is incorrect — trimetazidine does not release NO; its mechanism is 3-KAT inhibition.
Option D: Option D is incorrect — isosorbide mononitrate does not open KATP channels.
14. A resident rotating through a cardiology clinic in the United States reviews an international cardiology guideline that lists nicorandil as a second-line antianginal option. The resident asks the attending whether nicorandil can be prescribed for a patient with refractory stable angina. Which of the following is the most accurate response?
A) Nicorandil is FDA-approved for refractory stable angina in the United States as a second-line agent when beta-blockers and calcium channel blockers have failed to provide adequate symptom control
B) Nicorandil is not FDA-approved and is not available in the United States; it is available in the United Kingdom, Europe, Japan, Australia, and other countries; the ESC 2019 chronic coronary syndromes guidelines assign it a Class IIb recommendation as second-line add-on therapy; US clinicians managing refractory angina must rely on other approved agents such as ranolazine or ivabradine
C) Nicorandil received FDA approval in 2018 for stable angina in patients with documented coronary artery disease who have failed at least two conventional antianginal agents, but it remains largely unused in the United States due to cost and limited awareness
D) Nicorandil is available in the United States as a compounded preparation through specialty pharmacies under an FDA enforcement discretion policy, making it accessible for refractory angina when standard agents have failed
E) Nicorandil was withdrawn from US markets in 2012 following the European Medicines Agency restriction on its use due to the risk of Parkinsonian adverse effects, and it is no longer available in any major Western market
ANSWER: B
Rationale:
Nicorandil has never received FDA approval and is not commercially available in the United States. A US clinician cannot legally prescribe it through standard pharmacy channels, and no FDA enforcement discretion policy exists for this indication. Nicorandil is approved and used in the United Kingdom, Europe (including France and Germany), Japan, Australia, Canada, and much of Asia. The ESC 2019 Guidelines on Chronic Coronary Syndromes (Knuuti et al., Eur Heart J, 2020) assign nicorandil a Class IIb, Level B recommendation as a second-line add-on antianginal agent in patients with symptoms not adequately controlled by first-line therapy. For a US clinician managing a patient with refractory stable angina, the approved add-on options are ranolazine (FDA-approved for chronic stable angina as add-on therapy) and ivabradine (FDA-approved for stable angina in sinus rhythm with HR ≥70 bpm on maximum tolerated beta-blocker).
Option A: Option A is incorrect — nicorandil is not FDA-approved for any indication in the US.
Option C: Option C is incorrect — no such 2018 FDA approval occurred.
Option D: Option D is incorrect — no FDA enforcement discretion policy exists for nicorandil.
Option E: Option E incorrectly attributes the 2012 EMA restriction to nicorandil; that restriction was applied to trimetazidine due to Parkinsonian adverse effects, not nicorandil. Nicorandil's primary regulatory concern is mucocutaneous ulceration, not Parkinsonian effects.
15. A 67-year-old man in the United Kingdom has been on nicorandil 20 mg twice daily for stable angina for 14 months. He presents with a painful, non-healing ulcer on the perianal skin that has been present for 8 weeks and has not responded to local wound care. Colonoscopy and dermatology evaluation find no evidence of inflammatory bowel disease, malignancy, or infection. Which of the following is the most likely explanation and appropriate management?
A) The perianal ulceration is caused by nicorandil-induced hypotension reducing local tissue perfusion; the drug should be continued but the dose reduced to 10 mg twice daily and topical vasodilating agents applied to improve local blood flow
B) The ulceration represents a nitrate-tolerance phenomenon in which cross-tolerance to nicorandil's nitrate component produces ischemic mucosal changes; a nitrate-free interval should be instituted and nicorandil continued on an intermittent dosing schedule
C) The perianal ulcer is a coincidental finding unrelated to nicorandil; the drug should be continued and the ulcer managed with standard wound care, systemic antibiotics, and surgical referral if healing does not occur within 12 weeks
D) Nicorandil causes mucocutaneous ulceration — a distinctive and serious adverse effect in which the drug produces large, painful, slow-healing ulcers that can affect the oral mucosa, gastrointestinal tract, perianal region, and skin; the mechanism is poorly understood and not related to vascular compromise; nicorandil must be discontinued, after which the ulcers typically heal
E) The perianal ulceration is caused by nicorandil-induced thrombocytopenia leading to impaired wound healing; a complete blood count should be obtained and the drug discontinued only if platelet count is below 50,000 per microliter
ANSWER: D
Rationale:
Mucocutaneous ulceration is the most distinctive and clinically important serious adverse effect of nicorandil, and the scenario describes it precisely — a painful, non-healing perianal ulcer appearing after more than one year of nicorandil therapy, with all other causes excluded by appropriate investigation. Nicorandil can cause ulcers affecting the oral mucosa, esophagus, small bowel, colon, perianal region, and skin. These ulcers are characteristically large, painful, and very slow to heal with standard wound care. The mechanism is poorly understood and is not related to either of nicorandil's pharmacological mechanisms (KATP channel opening or NO release/cGMP pathway); it appears to be an idiosyncratic tissue-level effect. The critical management step is discontinuation of nicorandil — after the drug is stopped, ulcers typically heal, often completely, though this may take weeks to months for larger lesions. Failure to identify nicorandil as the cause leads to prolonged patient suffering and inappropriate escalation of wound management.
Option A: Option A is incorrect — mucocutaneous ulceration is not a vascular insufficiency phenomenon and is not dose-reversible by reduction alone; discontinuation is required.
Option B: Option B is incorrect — this adverse effect is unrelated to nitrate tolerance or nicorandil's nitrate component; intermittent dosing does not resolve it.
Option C: Option C is incorrect — the clinical context (14 months of nicorandil, unexplained ulcer, negative workup) makes nicorandil the most likely cause and should not be dismissed.
Option E: Option E is incorrect — nicorandil does not cause thrombocytopenia; the ulceration mechanism is not hematological.
16. The IONA trial (IONA Study Group, Lancet, 2002) was a landmark study for a newer antianginal agent. Which of the following correctly describes the IONA trial and its significance?
A) The IONA trial enrolled 5,126 patients with stable angina and randomized them to nicorandil 10-20 mg twice daily versus placebo on top of standard antianginal therapy; the primary endpoint — a composite of coronary heart disease death, nonfatal myocardial infarction, and unplanned hospital admission for chest pain — was significantly reduced by 17%; this made IONA the first antianginal trial beyond beta-blocker therapy post-myocardial infarction to demonstrate a significant reduction in hard cardiovascular endpoints in stable angina
B) The IONA trial enrolled 5,126 patients with stable angina and demonstrated that nicorandil significantly reduced all-cause mortality compared to placebo over a median follow-up of 1.6 years, establishing it as a mortality-reducing antianginal agent alongside beta-blockers
C) The IONA trial enrolled 19,102 patients with stable coronary artery disease and demonstrated that nicorandil 20 mg twice daily reduced the composite of cardiovascular death and nonfatal myocardial infarction by 17% in the overall population and by 22% in patients with baseline heart rate above 70 bpm
D) The IONA trial enrolled 5,126 patients with non-ST-elevation acute coronary syndrome and demonstrated that nicorandil added to standard ACS therapy significantly reduced recurrent ischemia and new-onset atrial fibrillation during the index hospitalization
E) The IONA trial enrolled 823 patients with stable angina on background beta-blocker or calcium channel blocker therapy and demonstrated that nicorandil significantly improved exercise duration and time to angina onset compared to placebo, without altering heart rate or blood pressure
ANSWER: A
Rationale:
The IONA (Impact Of Nicorandil in Angina) trial was the pivotal outcomes study for nicorandil and remains its strongest evidence for efficacy in stable angina. It enrolled 5,126 patients with stable angina who were randomized to nicorandil 10-20 mg twice daily or placebo in addition to their existing standard antianginal therapy. The primary composite endpoint — coronary heart disease (CHD) death, nonfatal myocardial infarction, or unplanned hospital admission for chest pain — was significantly reduced by 17% in the nicorandil group. The clinical significance of IONA lies in its claim to be the first antianginal trial in stable angina (other than beta-blocker therapy post-MI, where mortality benefit is well-established) to demonstrate a statistically significant reduction in hard cardiovascular endpoints. This finding has generated some debate because of heterogeneity in the primary endpoint — the composite includes the soft endpoint of unplanned chest pain hospitalization, which inflates the composite count. Nicorandil has not been shown to reduce all-cause or cardiovascular mortality. These considerations explain the ESC Class IIb (rather than stronger) recommendation.
Option B: Option B is incorrect — IONA did not demonstrate mortality reduction; all-cause mortality was not significantly affected.
Option C: Option C incorrectly attributes SIGNIFY's enrollment number and population to IONA.
Option D: Option D incorrectly describes an ACS population — IONA enrolled stable angina patients.
Option E: Option E describes a design similar to the CARISA trial (ranolazine), not IONA.
17. A cardiologist in France is explaining trimetazidine's mechanism of action to a resident. Trimetazidine reduces myocardial ischemic injury without altering heart rate, blood pressure, or contractility. Which of the following correctly describes how it achieves this?
A) Trimetazidine inhibits the Na+/Ca2+ exchanger (NCX) in cardiac myocytes, reducing intracellular calcium overload during ischemia and improving diastolic relaxation without affecting systemic hemodynamics
B) Trimetazidine opens mitochondrial ATP-sensitive potassium channels (KATP channels), triggering a preconditioning response that reduces infarct size during ischemia; heart rate and blood pressure are unaffected because the effect is confined to the mitochondrial compartment
C) Trimetazidine inhibits mitochondrial long-chain 3-ketoacyl-CoA thiolase (3-KAT) — the final enzyme in the beta-oxidation pathway for long-chain fatty acids — partially shifting myocardial substrate utilization from fatty acid oxidation toward glucose oxidation; glucose oxidation generates more ATP per unit of oxygen consumed and produces less intracellular acidosis during ischemia, reducing ischemic myocyte injury without any alteration of heart rate, blood pressure, or contractility
D) Trimetazidine inhibits late INa in cardiac myocytes, reducing intracellular sodium and calcium accumulation during ischemia through the same mechanism as ranolazine, but with greater metabolic specificity due to preferential binding at mitochondrial sodium channels
E) Trimetazidine inhibits carnitine palmitoyltransferase I (CPT-I), the enzyme that transfers long-chain fatty acyl groups across the inner mitochondrial membrane, completely blocking fatty acid entry into the mitochondria and forcing total reliance on glucose as the sole myocardial fuel source
ANSWER: C
Rationale:
Trimetazidine is a metabolic anti-ischemic agent — it reduces ischemic myocyte injury by modifying how the heart generates energy during ischemia, without any hemodynamic effect whatsoever. Under normal aerobic conditions, the myocardium preferentially metabolizes fatty acids (~60-70% of ATP generation) because fatty acids yield more ATP per molecule. However, during ischemia, fatty acid oxidation becomes metabolically disadvantageous: more O2 is consumed per ATP generated (lower oxygen efficiency), and incomplete fatty acid oxidation yields H+ ions and toxic lipid intermediates, worsening intracellular acidosis. Trimetazidine selectively inhibits mitochondrial long-chain 3-ketoacyl-CoA thiolase (3-KAT), the final enzyme in the beta-oxidation cycle for long-chain fatty acids. This partial inhibition shifts the metabolic balance toward glucose oxidation, which generates more ATP per unit of O2 consumed (higher oxygen efficiency) and produces less acidosis during ischemia, protecting myocytes from ischemic metabolic injury. Because this mechanism operates entirely at the mitochondrial level within cardiac myocytes, there are no hemodynamic consequences: heart rate, blood pressure, and contractility are unchanged.
Option A: Option A describes ranolazine's mechanism (NCX/late INa pathway), not trimetazidine's.
Option B: Option B describes the mitochondrial KATP preconditioning mechanism of nicorandil, not trimetazidine.
Option D: Option D incorrectly attributes late INa inhibition to trimetazidine.
Option E: Option E describes CPT-I inhibition (the mechanism of perhexiline, an older agent) — trimetazidine acts further downstream at 3-KAT, not at the mitochondrial membrane transport step; trimetazidine also produces partial, not complete, fatty acid oxidation inhibition.
18. A sports medicine physician asks a pharmacologist about trimetazidine's regulatory status across different jurisdictions, having encountered it in the context of an athlete's medication list. Which of the following correctly describes trimetazidine's current availability and regulatory standing?
A) Trimetazidine is FDA-approved in the United States for stable angina as add-on therapy in patients who remain symptomatic on beta-blockers and calcium channel blockers; it is also on the WADA Prohibited List for specified sports due to concerns about performance enhancement at supratherapeutic doses
B) Trimetazidine is FDA-approved in the United States and available in most Western countries, but the European Medicines Agency (EMA) restricted its indications in 2012 to patients over 75 years of age due to concerns about renal accumulation in younger patients
C) Trimetazidine is available in the United States as an orphan drug designation for refractory angina in patients with non-revascularizable coronary disease, with full FDA approval pending a phase 3 outcomes trial currently in progress
D) Trimetazidine was withdrawn from all markets globally in 2012 following EMA restriction, and is no longer available in any country for therapeutic use; its continued appearance on WADA lists reflects a residual prohibition from the pre-withdrawal period that has not been updated
E) Trimetazidine is not available in the United States (it has never received FDA approval) and is available in Europe, Asia, and Latin America; the EMA restricted its indications in 2012 due to neurological adverse effects including Parkinson-like symptoms; the ESC 2019 guidelines assign it a Class IIb recommendation as second-line add-on therapy for stable angina; and trimetazidine is prohibited by the World Anti-Doping Agency (WADA) in competition for specified sports, meaning athletes subject to anti-doping rules must be informed before it is prescribed
ANSWER: E
Rationale:
Trimetazidine's regulatory profile is complex and spans multiple jurisdictions, making it essential for clinicians working in international or sports medicine contexts to be familiar with the full picture. In the United States, trimetazidine has never received FDA approval and is not commercially available through any regulatory pathway. It is approved and used in Europe (though with restricted indications since 2012), Asia, and Latin America. The European Medicines Agency (EMA) restricted trimetazidine's approved indications in 2012 specifically because of neurological adverse effects — Parkinson-like symptoms including tremor, rigidity, bradykinesia, and gait disturbance that can occur with chronic use, possibly due to dopaminergic pathway interference. This restriction excluded patients with movement disorders and limited use to patients without neurological vulnerability. The ESC 2019 Guidelines on Chronic Coronary Syndromes assign trimetazidine a Class IIb, Level B recommendation as a second-line add-on agent for stable angina. Perhaps most importantly for the sports medicine context in the question, trimetazidine is listed on the WADA (World Anti-Doping Agency) Prohibited List as a prohibited substance in competition for specified sports. Any athlete subject to anti-doping rules must be informed of this prohibition before trimetazidine is prescribed.
Option A: Option A is incorrect — trimetazidine has never received FDA approval.
Option B: Option B is incorrect — the EMA restriction was based on neurological adverse effects, not renal accumulation; the age restriction described is inaccurate.
Option C: Option C is incorrect — no orphan drug designation or pending FDA approval exists for trimetazidine.
Option D: Option D is incorrect — trimetazidine was not withdrawn from all markets; it continues to be used in Europe, Asia, and Latin America with restricted indications.
19. A 71-year-old man in Germany has been taking trimetazidine 35 mg twice daily for stable angina for 3 years. He presents to his neurologist with a 6-month history of progressive bilateral hand tremor, rigidity on passive limb movement, and shuffling gait. Brain MRI is normal. Dopamine transporter (DaT) imaging is normal. Which of the following best explains this presentation and the appropriate management?
A) Trimetazidine causes cerebellar toxicity through mitochondrial inhibition in Purkinje cells, producing a progressive cerebellar ataxia that is clinically indistinguishable from idiopathic cerebellar degeneration; the drug should be discontinued and patients referred for neurogenetic testing
B) Trimetazidine can cause Parkinson-like symptoms — including tremor, rigidity, bradykinesia, and gait disturbance — with chronic use, possibly through interference with dopaminergic pathways; normal DaT imaging distinguishes this drug-induced parkinsonian syndrome from idiopathic Parkinson's disease; trimetazidine must be discontinued, and the symptoms are generally reversible after cessation, though recovery may take weeks to months
C) The neurological presentation is caused by trimetazidine-induced thiamine (vitamin B1) deficiency through competitive inhibition of thiamine pyrophosphokinase; the drug should be discontinued and high-dose thiamine replacement initiated immediately to prevent Wernicke's encephalopathy
D) Trimetazidine produces serotonin syndrome through inhibition of monoamine oxidase in the basal ganglia; the presentation mimics parkinsonism but is distinguished by the presence of autonomic instability; cyproheptadine should be initiated and trimetazidine discontinued
E) The neurological findings are unrelated to trimetazidine; 3-KAT (long-chain 3-ketoacyl-CoA thiolase) inhibition is confined to cardiac mitochondria and has no neurological off-target effects; the patient should undergo full evaluation for idiopathic Parkinson's disease including repeat DaT imaging in 12 months
ANSWER: B
Rationale:
Trimetazidine's most clinically important serious adverse effect is the development of Parkinson-like symptoms with chronic use. These include tremor, rigidity, bradykinesia, and gait disturbance — the cardinal features of parkinsonism. The mechanism is not fully established but is thought to involve interference with dopaminergic signaling pathways, as trimetazidine has structural similarities to compounds known to affect dopamine metabolism. The key diagnostic distinction between trimetazidine-induced drug-induced parkinsonism and idiopathic Parkinson's disease is dopamine transporter (DaT) imaging: in idiopathic Parkinson's disease, DaT imaging shows reduced striatal dopamine transporter binding because dopaminergic neurons are being lost; in drug-induced parkinsonism from trimetazidine (or other dopamine-blocking drugs), the dopaminergic neurons remain structurally intact and DaT imaging is normal — exactly as described in this patient. This diagnostic distinction is clinically important because it confirms that the parkinsonism is drug-induced and therefore potentially reversible. The appropriate management is discontinuation of trimetazidine, after which symptoms are generally reversible, though recovery may take weeks to months for established cases. This adverse effect was the basis for the European Medicines Agency's 2012 restriction of trimetazidine indications, which excluded patients with movement disorders.
Option A: Option A is incorrect — trimetazidine does not cause cerebellar toxicity; the presentation described is parkinsonism, not cerebellar ataxia.
Option C: Option C is incorrect — no thiamine deficiency mechanism has been established for trimetazidine.
Option D: Option D is incorrect — trimetazidine is not a monoamine oxidase inhibitor and does not cause serotonin syndrome.
Option E: Option E is incorrect — drug-induced parkinsonism from trimetazidine is well-established; normal DaT imaging directly points away from idiopathic Parkinson's disease and toward a drug-induced cause that should be addressed immediately.
20. A 63-year-old woman with stable angina has a resting heart rate of 52 bpm and blood pressure of 104/66 mmHg on maximally tolerated doses of metoprolol succinate and amlodipine. She continues to have two to three anginal episodes per week. Her cardiologist wants to add a third antianginal agent. Which class of agents is most appropriate to consider, and why?
A) A non-dihydropyridine calcium channel blocker such as verapamil, because it provides additional heart rate reduction through a distinct receptor mechanism from beta-blockers, without significantly lowering blood pressure in this setting
B) A long-acting nitrate such as isosorbide mononitrate, because nitrate-induced preload reduction will offset the hemodynamic burden in a patient with low blood pressure without affecting heart rate or contractility
C) Ivabradine, because its rate-dependent mechanism provides proportionally greater heart rate reduction at lower baseline rates, making it more effective the lower the heart rate is at baseline
D) A non-hemodynamic antianginal agent — either ranolazine (via late INa inhibition) or trimetazidine (via metabolic shift from fatty acid to glucose oxidation) — because these agents reduce myocardial ischemia without altering heart rate, blood pressure, or contractility, making them the appropriate class when hemodynamic reserve is exhausted by conventional therapy
E) Nicorandil, because its KATP-opening mechanism reduces afterload without any preload effect, making it hemodynamically neutral and therefore safe to add when blood pressure is already low
ANSWER: D
Rationale:
This patient presents the classic scenario in which conventional hemodynamic antianginal agents have reached their limit: a resting heart rate of 52 bpm rules out ivabradine (contraindicated with resting HR <60 bpm before initiation) and precludes beta-blocker uptitration; a blood pressure of 104/66 mmHg makes adding nitrates (preload reduction) or a non-dihydropyridine CCB (further BP lowering plus negative inotropy) likely to cause symptomatic hypotension or syncope. The fundamental distinction in antianginal pharmacology is between hemodynamic agents — which reduce myocardial oxygen demand by altering heart rate, preload, afterload, or contractility — and non-hemodynamic agents — which reduce ischemic injury at the cellular or metabolic level without cardiovascular hemodynamic effects. Ranolazine (late INa inhibition) and trimetazidine (3-KAT inhibition/metabolic shift) are the prototypical non-hemodynamic antianginal agents. Adding ranolazine in this context would provide anti-ischemic benefit without further lowering HR or BP. In the US, ranolazine is the appropriate choice (FDA-approved); trimetazidine would be appropriate in jurisdictions where it is available.
Option A: Option A is incorrect — verapamil has significant negative chronotropic and hypotensive effects; adding it to this patient would compound both problems.
Option B: Option B is incorrect — nitrates are hemodynamic (preload reduction causes further BP fall); adding isosorbide mononitrate to a patient already at 104/66 mmHg risks symptomatic hypotension.
Option C: Option C is incorrect — ivabradine's rate-dependent mechanism does not amplify effect at low baseline rates; the rate-dependent property means the drug has less effect (not more) when HR is already low; and HR of 52 bpm is below the contraindication threshold.
Option E: Option E is incorrect — nicorandil is partially hemodynamic (combined KATP + nitrate mechanism reduces both afterload and preload); it is not available in the US and would lower BP further.
21. A 74-year-old man with stable angina, heart failure with preserved ejection fraction (HFpEF), and permanent atrial fibrillation is on digoxin 0.125 mg daily (steady-state level 0.8 ng/mL), furosemide, and bisoprolol. His cardiologist adds ranolazine 500 mg twice daily for persistent angina. Two weeks later he presents with nausea, decreased appetite, and a new first-degree AV block on ECG. His digoxin level is now 1.9 ng/mL. Which of the following best explains the elevated digoxin level?
A) Ranolazine inhibits P-glycoprotein (P-gp), a drug transporter that normally limits intestinal absorption and promotes renal tubular secretion of digoxin; P-gp inhibition by ranolazine increases digoxin bioavailability and reduces its renal clearance, raising plasma digoxin levels by approximately 1.5-fold; when ranolazine is added to a digoxin regimen, digoxin levels must be monitored and the dose reduced accordingly
B) Ranolazine inhibits CYP3A4 in the liver, reducing hepatic metabolism of digoxin and increasing its plasma concentration; this interaction is managed by reducing the ranolazine dose to 500 mg twice daily when co-administered with digoxin
C) Ranolazine displaces digoxin from plasma protein binding sites, acutely raising the free (unbound) digoxin fraction without changing the total digoxin level; the toxicity results from the increased free fraction rather than an absolute rise in total digoxin concentration
D) Ranolazine inhibits the organic anion transporting polypeptide (OATP1B1) in hepatic sinusoids, reducing biliary excretion of digoxin and causing enterohepatic recirculation that progressively raises plasma levels over several weeks
E) Ranolazine competitively inhibits the renal organic cation transporter (OCT2) responsible for digoxin tubular secretion, reducing renal elimination without affecting intestinal absorption; the interaction magnitude is unpredictable and monitoring is not routinely recommended
ANSWER: A
Rationale:
Digoxin is a substrate of P-glycoprotein (P-gp), an efflux transporter that plays two roles in digoxin disposition: in the gut, P-gp limits intestinal absorption by pumping digoxin back into the intestinal lumen; in the kidney, P-gp promotes tubular secretion of digoxin into the urine. Ranolazine is a P-gp inhibitor. When ranolazine inhibits P-gp, both of these effects are attenuated: intestinal absorption of digoxin increases (higher bioavailability) and renal tubular secretion of digoxin decreases (reduced clearance). The combined result is a rise in steady-state digoxin plasma levels of approximately 1.5-fold, as documented in the ranolazine prescribing information and pharmacokinetic interaction studies. In this patient, the digoxin level rose from 0.8 ng/mL to 1.9 ng/mL — a 2.4-fold increase, which is consistent with this interaction compounded by any concurrent change in renal function or electrolytes (digoxin toxicity risk rises sharply with hypokalemia, common in furosemide-treated patients). The appropriate management when adding ranolazine to a digoxin regimen is to measure digoxin levels after starting ranolazine and adjust the digoxin dose downward to keep levels in the therapeutic range (0.5-0.9 ng/mL for rate control in AF).
Option B: Option B is incorrect — digoxin is not significantly metabolized by CYP3A4; its primary elimination route is renal excretion as unchanged drug via P-gp-mediated tubular secretion.
Option C: Option C is incorrect — digoxin has low plasma protein binding (~25%); protein binding displacement is not a clinically significant mechanism for this interaction.
Option D: Option D is incorrect — OATP1B1 is a hepatic uptake transporter relevant to statins; digoxin is not primarily eliminated via biliary excretion or enterohepatic recirculation.
Option E: Option E is incorrect — the primary mechanism is P-gp inhibition, not OCT2; monitoring digoxin levels is explicitly recommended in the prescribing information when ranolazine is co-administered.
22. A 61-year-old man with stable angina is on diltiazem ER 360 mg once daily for combined antianginal benefit and rate control. His resting heart rate is 68 bpm and blood pressure is 128/78 mmHg. His cardiologist considers adding ivabradine for additional heart rate reduction and antianginal effect. Which of the following best describes the pharmacological concerns with this combination?
A) Diltiazem and ivabradine can be safely combined at standard doses because diltiazem's L-type calcium channel blockade and ivabradine's HCN channel blockade act through entirely different mechanisms with no pharmacokinetic interaction; the combination provides complementary antianginal benefit without additive risk
B) Diltiazem is a strong CYP3A4 inhibitor that raises ivabradine levels 7-8 fold, creating a contraindicated combination analogous to the ketoconazole-ivabradine interaction; ivabradine must not be used in any patient receiving diltiazem regardless of dose
C) Diltiazem creates a dual pharmacological problem when combined with ivabradine: it is a moderate CYP3A4 inhibitor that increases ivabradine plasma levels 1.5- to 2-fold, raising exposure and adverse effect risk; and it independently reduces heart rate through AV nodal calcium channel blockade, producing additive bradycardia when combined with ivabradine's If-mediated heart rate reduction; the combination should be avoided if possible, and if used, ivabradine must be limited to the lowest effective dose with close heart rate monitoring
D) The primary concern with diltiazem plus ivabradine is additive QTc prolongation; diltiazem prolongs QTc through hERG channel blockade and ivabradine prolongs QTc through HCN channel effects on repolarization; a baseline and follow-up ECG within 2 weeks is mandatory
E) Diltiazem inhibits CYP2D6, raising ivabradine levels by approximately 3-fold; because ivabradine is eliminated almost entirely via CYP2D6, poor CYP2D6 metabolizers on diltiazem are at particularly high risk of ivabradine toxicity and require genotype testing before the combination is initiated
ANSWER: C
Rationale:
The combination of diltiazem and ivabradine presents two distinct and compounding pharmacological problems. First, the pharmacokinetic problem: ivabradine is extensively metabolized by CYP3A4 (cytochrome P450 3A4). Diltiazem is a moderate CYP3A4 inhibitor. Co-administration of diltiazem with ivabradine raises ivabradine plasma levels approximately 1.5- to 2-fold — a meaningful increase that elevates the risk of dose-related adverse effects, most importantly bradycardia and phosphenes. Second, the pharmacodynamic problem: diltiazem is a non-dihydropyridine calcium channel blocker that slows AV nodal conduction and reduces heart rate by blocking L-type calcium channels in nodal tissue. Ivabradine independently reduces heart rate through HCN/If channel blockade in the sinoatrial node. These two mechanisms for heart rate reduction are additive: combining them produces a greater degree of heart rate lowering than either agent alone, increasing the risk of clinically significant bradycardia (HR <50 bpm) and its consequences. For these reasons, diltiazem (and verapamil, which has similar dual concerns) represents a relative contraindication to ivabradine — the prescribing information advises avoiding this combination if possible. If clinical circumstances require both agents, ivabradine should be restricted to the lowest effective dose and resting heart rate monitored closely.
Option A: Option A is incorrect — there is both a pharmacokinetic interaction (CYP3A4) and a pharmacodynamic interaction (additive HR reduction); the statement that there is no interaction is false.
Option B: Option B is incorrect — diltiazem is a moderate CYP3A4 inhibitor, not a strong one; the magnitude of level increase (~1.5-2 fold) differs substantially from that seen with strong inhibitors like ketoconazole (~7-8 fold); diltiazem co-administration is a relative contraindication requiring dose limitation, not an absolute contraindication analogous to ketoconazole.
Option D: Option D is incorrect — ivabradine does not prolong QTc; one of its advantages is the complete absence of effect on ventricular repolarization; and diltiazem is not a significant hERG blocker.
Option E: Option E is incorrect — ivabradine is a CYP3A4 substrate, not a CYP2D6 substrate; diltiazem's relevant enzyme inhibition is CYP3A4, not CYP2D6.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.